Volume : 13, Issue : 07, July – 2026

Title:

GASTRORETENTIVE DRUG DELIVERY SYSTEMS: CLASSIFICATION, MECHANISMS, FORMULATION STRATEGIES, EVALUATION, THERAPEUTIC APPLICATIONS, AND RECENT ADVANCES

Authors :

Bhagyashri S. Gaikwad, K. A. Zagade, Ramesh D. Ingole, Pooja A. Borawake, Amol B. Dabhade, Kshitijkumar G. Wagh

Abstract :

Gastroretentive drug delivery systems (GRDDS) have surfaced as a viable oral drug administration method to address the challenges posed by fast stomach emptying and inadequate bioavailability of traditional dose forms. By extending stomach retention duration, GRDDS augment medication solubility, promote absorption in the upper gastrointestinal region, and deliver prolonged therapeutic effects. This assessment encapsulates the physiological foundations of gastric retention, biopharmaceutical factors, and the diverse classification methods of gastroretentive systems, such as floating, high-density, mucoadhesive, expandable, swellable, superporous hydrogel, raft-forming, and magnetic systems. The study moreover examines elements influencing gastroretention, frequently utilized polymers and excipients, assessment techniques, therapeutic uses, and current technological innovations. Innovative approaches like nanotechnology and three-dimensional printing have significantly enhanced the capabilities of GRDDS in optimizing oral medication administration. In general, gastroretentive systems serve as a potent framework for improving therapeutic effectiveness, patient adherence, and formulation efficiency, while presenting considerable prospects for the advancement of sophisticated controlled-release pharmaceutical formulations.
Keywords: Gastroretentive drug delivery systems, Gastric retention, Floating drug delivery system, Controlled drug release, Oral drug delivery, Bioavailability, Mucoadhesive systems, Gastrointestinal tract, Sustained release, Polymers.

Cite This Article:

Please cite this article in press Bhagyashri S. Gaikwad et al., Gastroretentive Drug Delivery Systems: Classification, Mechanisms, Formulation Strategies, Evaluation, Therapeutic Applications, And Recent Advances.,, Indo Am. J. P. Sci, 2026; 13(07).

REFERENCES:

1. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 6th ed. London: Elsevier; 2022.
2. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
3. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. J Control Release. 2003;90(2):143-62.
4. Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm. 1996;136(1-2):117-39.
5. Lopes CM, Lobo JMS, Costa P. Formas farmacêuticas de libertação modificada: polímeros hidrofílicos. Rev Bras Cienc Farm. 2005;41(2):143-54.
6. Timmermans J, Moës AJ. Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules. Int J Pharm. 1990;62(2-3):207-16.
7. Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug Dev Ind Pharm. 1996;22(6):531-9.
8. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006;3(2):217-33.
9. Tortora GJ, Derrickson B. Principles of Anatomy and Physiology. 16th ed. Hoboken (NJ): John Wiley & Sons; 2021.
10. Hall JE. Guyton and Hall Textbook of Medical Physiology. 15th ed. Philadelphia: Elsevier; 2024.
11. Chawla G, Gupta P, Koradia V, Bansal AK. Gastroretention: a means to address regional variability in intestinal drug absorption. Pharm Technol. 2003;27(7):50-68.
12. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, et al. Upper gastrointestinal pH in young, healthy men and women. Pharm Res. 1990;7(7):756-61.
13. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005;57(11):1556-68.
14. Wilson CG, Washington N. The stomach: its role in oral drug delivery. In: Rubinstein MH, editor. Physiological Pharmaceutical Technology. Chichester: Ellis Horwood; 1989. p. 47-70.
15. Davis SS. Formulation strategies for absorption windows. Drug Discov Today. 2005;10(4):249-57.
16. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-20.
17. Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000;63(3):235-59.
18. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low density foam powder: effects of formulation and processing parameters. Int J Pharm. 2003;253(1-2):151-9.
19. Hoffman A. Pharmacodynamic aspects of sustained release preparations. Adv Drug Deliv Rev. 1998;33(3):185-99.
20. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. AAPS PharmSciTech. 2005;6(3):E372-E390.
21. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release. 2006;111(1-2):1-18.
22. Nayak AK, Maji R, Das B. Gastroretentive drug delivery systems: a review. Asian J Pharm Clin Res. 2010;3(1):2-10.
23. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst. 1998;15(3):243-84.
24. Ponchel G, Irache JM. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev. 1998;34(2-3):191-219.
25. Kedzierewicz F, Thouvenot P, Lemut J, Etienne A, Hoffman M, Maincent P. Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J Control Release. 1999;58(2):195-205.
26. Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance. Pharm Sci Technol Today. 2000;3(6):198-204.
27. Chen J, Park K. Synthesis and characterization of superporous hydrogel composites. J Control Release. 2000;65(1-2):73-82.
28. Washington N. Investigation into the barrier action of an alginate gastric reflux suppressant, Liquid Gaviscon. Drug Invest. 1991;3(1):23-30.
29. Groning R, Heun G. Oral dosage forms with controlled gastrointestinal transit. Drug Dev Ind Pharm. 1984;10(4):527-39.
30. Streubel A, Siepmann J, Bodmeier R. Drug delivery to the upper small intestine window using gastroretentive technologies. Curr Opin Pharmacol. 2006;6(5):501-8.
31. Mojaverian P, Vlasses PH, Kellner PE, Rocci ML Jr. Effects of gender, posture and age on gastric residence time of an indigestible solid. Pharm Res. 1988;5(10):639-44.
32. Wilding IR, Coupe AJ, Davis SS. The role of gamma scintigraphy in oral drug delivery. Adv Drug Deliv Rev. 2001;46(1-3):103-24.
33. Robinson JR, Lee VHL. Controlled Drug Delivery: Fundamentals and Applications. 2nd ed. New York: Marcel Dekker; 1987.
34. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 9th ed. London: Pharmaceutical Press; 2020.
35. Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics. 8th ed. New York: McGraw-Hill Education; 2022.
36. Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop J Pharm Res. 2008;7(3):1055-66.
37. Sriamornsak P. Chemistry of pectin and its pharmaceutical uses: a review. Silpakorn Univ Int J. 2003;3(1-2):206-28.
38. Thombre AG. Assessment of feasibility of oral controlled release systems. Drug Dev Ind Pharm. 2005;31(4-5):331-7.
39. Siepmann J, Peppas NA. Hydrophilic matrices for controlled drug delivery: an improved mathematical model to predict the resulting drug release kinetics. Pharm Res. 2000;17(10):1290-8.
40. Baumgartner S, Kristl J, Vrečer F, Vodopivec P, Zorko B. Optimisation of floating matrix tablets and evaluation of their gastric residence time. Int J Pharm. 2000;195(1-2):125-35.
41. Ahuja A, Khar RK, Ali J. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm. 1997;23(5):489-515.
42. United States Pharmacopeia and National Formulary (USP 47–NF 42). Rockville (MD): United States Pharmacopeial Convention; 2024.
43. Indian Pharmacopoeia Commission. Indian Pharmacopoeia 2022. 9th ed. Ghaziabad: IPC; 2022.
44. Rosa M, Zia H, Rhodes T. Design and testing of a low-density multiparticulate system for oral sustained release. Int J Pharm. 1994;105(1):65-70.
45. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13(2):123-33.
46. Davis SS, Hardy JG, Fara JW. Transit of pharmaceutical dosage forms through the small intestine. Gut. 1986;27(8):886-92.
47. International Council for Harmonisation (ICH). ICH Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.
48. Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: a review with special emphasis on floating drug delivery systems. Drug Deliv. 2011;18(2):97-110.
49. Choi BY, Park HJ, Hwang SJ, Park JB. Preparation of alginate beads for floating drug delivery system: effects of formulation parameters. Drug Dev Ind Pharm. 2002;28(5):559-68.
50. Bardonnet PL, Faivre V, Falson F. Gastroretentive dosage forms for the treatment of gastric diseases. Expert Opin Drug Deliv. 2008;5(6):671-85.
51. Singh LP, Sharma R, Prajapati SK. Gastroretentive drug delivery systems: current approaches and future prospects. J Pharm Res. 2011;4(7):2239-45.
52. Streubel A, Siepmann J, Bodmeier R. Multiple unit gastroretentive drug delivery systems: a new strategy for improving oral bioavailability. Pharm Res. 2003;20(5):756-62.
53. Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. Int J Pharm. 2016;510(1):144-58.
54. Patel A, Ray S, Thakur RS. In vitro and in vivo evaluation of gastroretentive dosage forms: recent advances and future perspectives. Asian J Pharm Sci. 2020;15(4):397-414.
55. Shaikh RP, Pillay V, Choonara YE, du Toit LC, Ndesendo VMK, Kumar P. Gastroretentive drug delivery systems: an overview of formulation approaches. J Pharm Sci. 2010;99(2):713-28.
56. Jamróz W, Szafraniec J, Kurek M, Jachowicz R. 3D printing in pharmaceutical and medical applications – recent achievements and challenges. Pharm Res. 2018;35(9):176.
57. Arora G, Malik K, Singh I, Arora S, Rana V. Recent advances in gastroretentive drug delivery systems: challenges and opportunities. Int J Pharm Investig. 2011;1(1):1-12.
58. Acosta-Vélez GF, Linsley CS, Zhu TZ, Wu W. 3D printing of pharmaceutical dosage forms: current status and future perspectives. AAPS PharmSciTech. 2023;24(2):69.